Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Phern Chern Tor, Nurmiati Amir, Johnson Fam, Roger Ho, Pichai Ittasakul, Margarita M Maramis, Benita Ponio, Dharmawan Ardi Purnama, Wanida Rattanasumawong, Elizabeth Rondain, Ahmad Hatim Bin Sulaiman, Kannokarn Wiroteurairuang & Kok Yoon Chee. (2022) A Southeast Asia Consensus on the Definition and Management of Treatment-Resistant Depression. Neuropsychiatric Disease and Treatment 18, pages 2747-2757.
Read now
Read now
Min Zhu, Siqi Xu, Xia Ju, Shengbin Wang & Xitong Yu. (2022) Effects of the Different Doses of Esketamine on Postoperative Quality of Recovery in Patients Undergoing Modified Radical Mastectomy: A Randomized, Double-Blind, Controlled Trial. Drug Design, Development and Therapy 16, pages 4291-4299.
Read now
Read now
Andrzej Pilc, Agata Machaczka, Paweł Kawalec, Jodi L. Smith & Jeffrey M. Witkin. (2022) Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Expert Opinion on Drug Discovery 17:10, pages 1131-1146.
Read now
Read now
Luke A. Jelen & James M. Stone. (2021) Ketamine for depression. International Review of Psychiatry 33:3, pages 207-228.
Read now
Read now
Articles from other publishers (40)
Nicolas A. Nunez, Boney Joseph, Rakesh Kumar, Ioanna Douka, Alessandro Miola, Larry J. Prokop, Brian J. Mickey & Balwinder Singh. (2023) An Update on the Efficacy of Single and Serial Intravenous Ketamine Infusions and Esketamine for Bipolar Depression: A Systematic Review and Meta-Analysis. Brain Sciences 13:12, pages 1672.
Crossref
Crossref
Barbara Chruścicka-Smaga, Agata Machaczka, Bernadeta Szewczyk & Andrzej Pilc. (2023) Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies. Pharmacological Reports 75:6, pages 1341-1349.
Crossref
Crossref
Dong Xu, Li-Na Gao, Xu-Jiao Song, Qin-Wei Dong, Yi-Bing Chen, Yuan-Lu Cui & Qiangsong Wang. (2023) Enhanced antidepressant effects of BDNF-quercetin alginate nanogels for depression therapy. Journal of Nanobiotechnology 21:1.
Crossref
Crossref
Karolina Wydra, Kacper Witek, Agata Suder & Małgorzata Filip. (2023) Esketamine Inhibits Cocaine-Seeking Behaviour Subsequent to Various Abstinence Conditions in Rats. Biomolecules 13:9, pages 1411.
Crossref
Crossref
Nadezhda Y. Davydova, David A. Hutner, Kari A. Gaither, Dilip Kumar Singh, Bhagwat Prasad & Dmitri R. Davydov. (2023) High-Throughput Assay of Cytochrome P450-Dependent Drug Demethylation Reactions and Its Use to Re-Evaluate the Pathways of Ketamine Metabolism. Biology 12:8, pages 1055.
Crossref
Crossref
Harry M Griffiths. (2023) Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice?. British Journal of Pain.
Crossref
Crossref
Tanguy Taillefer de Laportalière, Adeline Jullien, Antoine Yrondi, Philippe Cestac & François Montastruc. (2023) Reporting of harms in clinical trials of esketamine in depression: a systematic review. Psychological Medicine, pages 1-11.
Crossref
Crossref
Thiago Ângelo Smaniotto, Angela Maria Casaril, Darling de Andrade Lourenço, Fernanda S. Sousa, Fabiana K. Seixas, Tiago Collares, Rafael Woloski, Luciano da Silva Pinto, Diego Alves & Lucielli Savegnago. (2023) Intranasal administration of interleukin-4 ameliorates depression-like behavior and biochemical alterations in mouse submitted to the chronic unpredictable mild stress: modulation of neuroinflammation and oxidative stress. Psychopharmacology 240:4, pages 935-950.
Crossref
Crossref
Teng He, Di Wang, Zifeng Wu, Chaoli Huang, Xiangyang Xu, Xiangqing Xu, Cunming Liu, Kenji Hashimoto & Chun Yang. (2022) A bibliometric analysis of research on (R)-ketamine from 2002 to 2021. Neuropharmacology 218, pages 109207.
Crossref
Crossref
Fabian Schumacher, Alexander Carpinteiro, Michael J. Edwards, Gregory C. Wilson, Simone Keitsch, Matthias Soddemann, Barbara Wilker, Burkhard Kleuser, Katrin Anne Becker, Christian P. Müller, Johannes Kornhuber & Erich Gulbins. (2022) Stress induces major depressive disorder by a neutral sphingomyelinase 2-mediated accumulation of ceramide-enriched exosomes in the blood plasma. Journal of Molecular Medicine 100:10, pages 1493-1508.
Crossref
Crossref
Subbulakshmi Sundaram & Ashok Swaminathan Govindarajan. 2022. Ketamine Revisited - New Insights into NMDA Inhibitors. Ketamine Revisited - New Insights into NMDA Inhibitors.
Fabian Schumacher, Michael J. Edwards, Christiane Mühle, Alexander Carpinteiro, Greg C. Wilson, Barbara Wilker, Matthias Soddemann, Simone Keitsch, Norbert Scherbaum, Bernhard W. Müller, Undine E. Lang, Christoph Linnemann, Burkhard Kleuser, Christian P. Müller, Johannes Kornhuber & Erich Gulbins. (2022) Ceramide levels in blood plasma correlate with major depressive disorder severity and its neutralization abrogates depressive behavior in mice. Journal of Biological Chemistry 298:8, pages 102185.
Crossref
Crossref
Lai Fong Chan, Luke Sy-Cherng Woon, Nuur Asyikin Mohd Shukor, Choon Leng Eu, Nurazah Ismail, Song Jie Chin, Nik Ruzyanei Nik Jaafar & Azlin Baharudin. (2022) Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression. Frontiers in Psychiatry 13.
Crossref
Crossref
Hewa Artin, Sean Bentley, Eamonn Mehaffey, Fred X. Liu, Kevin Sojourner, Andrew W. Bismark, David Printz, Ellen E. Lee, Brian Martis, Sharon De Peralta, Dewleen G. Baker, Jyoti Mishra & Dhakshin Ramanathan. (2022) Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series. eClinicalMedicine 48, pages 101439.
Crossref
Crossref
Weicheng Li, Yanling Zhou, Weijian Liu, Chengyu Wang, Xiaofeng Lan, Zhipei Zhang, Fan Zhang, Yanxiang Ye, Haiyan Liu, Kai Wu, Roger S. McIntyre & Yuping Ning. (2022) Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study. Journal of Affective Disorders 300, pages 172-178.
Crossref
Crossref
Barbara J. Henry. (2022) Symptom Management in Oncology: Depression and Anxiety. Seminars in Oncology Nursing 38:1, pages 151251.
Crossref
Crossref
Anja S. Petersen, Adam S. Pedersen, Mads C. J. Barloese, Per Holm, Ole Pedersen, Rigmor H. Jensen & Agneta H. Snoer. (2021) Intranasal ketamine for acute cluster headache attacks—Results from a proof‐of‐concept open‐label trial. Headache: The Journal of Head and Face Pain 62:1, pages 26-35.
Crossref
Crossref
Bijia Song & Jun-Chao Zhu. (2021) Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review. Frontiers in Pharmacology 12.
Crossref
Crossref
Alice Caldiroli, Enrico Capuzzi, Ilaria Tagliabue, Martina Capellazzi, Matteo Marcatili, Francesco Mucci, Fabrizia Colmegna, Massimo Clerici, Massimiliano Buoli & Antonios Dakanalis. (2021) Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. International Journal of Molecular Sciences 22:23, pages 13070.
Crossref
Crossref
Rabie Karrouri, Zakaria Hammani, Roukaya Benjelloun & Yassine Otheman. (2021) Major depressive disorder: Validated treatments and future challenges. World Journal of Clinical Cases 9:31, pages 9350-9367.
Crossref
Crossref
Jolien K E Veraart, Sanne Y Smith-Apeldoorn, Iris M Bakker, Berber A E Visser, Jeanine Kamphuis, Robert A Schoevers & Daan J Touw. (2021) Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. International Journal of Neuropsychopharmacology 24:10, pages 808-831.
Crossref
Crossref
Xenia Gonda, Peter Dome, Joanna C. Neill & Frank I. Tarazi. (2021) Novel antidepressant drugs: Beyond monoamine targets. CNS Spectrums, pages 1-10.
Crossref
Crossref
Xue-Jie Qi, Dong Xu, Meng-Li Tian, Jin-Feng Zhou, Qiang-Song Wang & Yuan-Lu Cui. (2021) Thermosensitive hydrogel designed for improving the antidepressant activities of genipin via intranasal delivery. Materials & Design 206, pages 109816.
Crossref
Crossref
Linda Xing Yu Liu, Marina Golts & Virginia Fernandes. (2021) Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine. Pharmacy 9:3, pages 118.
Crossref
Crossref
Dongjiao An, Changwei Wei, Jing Wang & Anshi Wu. (2021) Intranasal Ketamine for Depression in Adults: A Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Frontiers in Psychology 12.
Crossref
Crossref
Kinga Pożarowska, Adam Rusinek, Gracjan Rudziński, Ewelina Soroka & Jolanta Masiak. (2021) New drugs in psychiatry - cariprazine, lurasidone, esketamine. Current Problems of Psychiatry 22:2, pages 111-124.
Crossref
Crossref
Marsal Sanches, Joao Quevedo & Jair C. Soares. (2021) New agents and perspectives in the pharmacological treatment of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 106, pages 110157.
Crossref
Crossref
Boldizsár Czéh & Maria Simon. (2021) Benefits of animal models to understand the pathophysiology of depressive disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 106, pages 110049.
Crossref
Crossref
Luke A Jelen, Allan H Young & James M Stone. (2020) Ketamine: A tale of two enantiomers. Journal of Psychopharmacology 35:2, pages 109-123.
Crossref
Crossref
Zhiqing Zhan, Xichao Wang, Qing Chen, Zhidai Xiao & Bin Zhang. (2021) Comparative efficacy and side-effect profile of ketamine and esketamine in the treatment of unipolar and bipolar depression: protocol for a systematic review and network meta-analysis. BMJ Open 11:2, pages e043457.
Crossref
Crossref
Gin S Malhi, Erica Bell, Darryl Bassett, Philip Boyce, Richard Bryant, Philip Hazell, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Richard Porter, Ajeet B Singh & Greg Murray. (2020) The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian & New Zealand Journal of Psychiatry 55:1, pages 7-117.
Crossref
Crossref
Jolien K E Veraart, Jeanine Kamphuis, Mathis Schlegel & Robert A Schoevers. (2021) Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities. BMJ Case Reports 14:1, pages e238135.
Crossref
Crossref
Milene Borsoi, Luis Eduardo D. Nunes, Amanda R. Barbosa, Mariana S. Lima, Isabelle Medeiros, Mariana A. Pranke, Camila B. Antonio, Stela M.K. Rates & Gilda A. Neves. (2021) Intermittent repeated stress but not ketamine changes mice response to antidepressants. Neuroscience Letters 741, pages 135452.
Crossref
Crossref
Piper A. Ranallo & Jessica D. Tenenbaum. 2021. Mental Health Informatics. Mental Health Informatics
1
30
.
Vincenzo Dattilo, Rosario Amato, Nicola Perrotti & Massimo Gennarelli. (2020) The Emerging Role of SGK1 (Serum- and Glucocorticoid-Regulated Kinase 1) in Major Depressive Disorder: Hypothesis and Mechanisms. Frontiers in Genetics 11.
Crossref
Crossref
Dong Xu, Yu-Ren Lu, Na Kou, Meng-Jiao Hu, Qiang-Song Wang & Yuan-Lu Cui. (2020) Intranasal delivery of icariin via a nanogel-thermoresponsive hydrogel compound system to improve its antidepressant-like activity. International Journal of Pharmaceutics 586, pages 119550.
Crossref
Crossref
Abby Pribish, Nicole Wood & Arun Kalava. (2020) A Review of Nonanesthetic Uses of Ketamine. Anesthesiology Research and Practice 2020, pages 1-15.
Crossref
Crossref
Lynnette A. Averill, Samar Fouda, James W. Murrough & Chadi G. Abdallah. 2020. Rapid Acting Antidepressants. Rapid Acting Antidepressants
163
194
.
Shigeyuki Chaki. 2020. Rapid Acting Antidepressants. Rapid Acting Antidepressants
289
309
.
Hewa Artin, Sean Bentley, Eamonn Mehaffey, Fred X. Liu, Kevin Sojourner, Andrew Bismark, David Printz, Ellen E. Lee, Brian Martis, Sharon De Peralta, Dewleen G. Baker, Jyoti Mishra & Dhakshin Ramanathan. (2021) Effects of Intranasal (S)-Ketamine on Veterans With Co-Morbid Treatment-Resistant Depression and PTSD. SSRN Electronic Journal.
Crossref
Crossref